Skip to main content
. Author manuscript; available in PMC: 2013 Jul 18.
Published in final edited form as: Clin Cancer Res. 2012 Aug 7;18(19):5290–5303. doi: 10.1158/1078-0432.CCR-12-0563

Table 1.

RECIST response rates in TRIA mice versus human melanoma

Regimen Mean day 0 tumor
volume (mm3)
Mean day 21 tumor
volume (mm3)
RECIST response
rate (CR + PR + SD)
Reported human response
rates for melanoma
Untreated 83 322   0%
Carboplatin 89 217 21% 14%–23%
Paclitaxel 62 182 21% 14–18%
Carboplatin/paclitaxel 41   97 38% 19%–47%
Temozolomide 88 266 10% 15% (10%–17%)
Sunitinib 63 115 32% 33%
AZD6244/BEZ235 53   29 63% Unknown